Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1995 6
1996 13
1997 2
1998 5
1999 5
2000 11
2001 9
2002 17
2003 15
2004 19
2005 18
2006 25
2007 21
2008 26
2009 23
2010 19
2011 21
2012 16
2013 14
2014 20
2015 13
2016 21
2017 18
2018 14
2019 18
2020 16
2021 18
2022 14
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M. Phinyo P, et al. J Allergy Clin Immunol Pract. 2021 Feb;9(2):956-970.e57. doi: 10.1016/j.jaip.2020.08.055. Epub 2020 Sep 8. J Allergy Clin Immunol Pract. 2021. PMID: 32916325
RESULTS: We identified and included 22 RCTs with 3943 patients for evidence synthesis. Olopatadine, fexofenadine, bilastine, rupatadine, and levocetirizine were more efficacious than placebo in TSS. Olopatadine was ranked first for all efficacy outcomes (TSS: SMD -1 …
RESULTS: We identified and included 22 RCTs with 3943 patients for evidence synthesis. Olopatadine, fexofenadine, bilastine, rupatadi …
OTC drugs for seasonal allergies.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60. Med Lett Drugs Ther. 2019. PMID: 31169808 No abstract available.
Olopatadine.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000577 Free Books & Documents. Review.
Because absorption from the eye is limited, olopatadine would not be expected to cause any adverse effects in breastfed infants. ...
Because absorption from the eye is limited, olopatadine would not be expected to cause any adverse effects in breastfed infants. ...
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Andrews CP, Mohar D, Salhi Y, Tantry SK. Andrews CP, et al. Ann Allergy Asthma Immunol. 2020 Feb;124(2):171-178.e2. doi: 10.1016/j.anai.2019.11.007. Epub 2019 Nov 15. Ann Allergy Asthma Immunol. 2020. PMID: 31734334 Free article. Clinical Trial.
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). ...METHODS: In this phase 2, double-blind, parallel-group study, patients (12 years of age) with SAR wer …
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and m …
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S, Sridhar S, Kumar K, Jayanthi CR, Gangasagara SB, Rathod BLS, Preethi B, Mittal P. Ayyappanavar S, et al. Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20. Indian J Ophthalmol. 2021. PMID: 33463568 Free PMC article. Clinical Trial.
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis. ...Each group was assigned to be treated with one of the three treatment …
PURPOSE: To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5 …
Dupilumab-Induced Follicular Conjunctivitis.
Shen E, Xie K, Jwo K, Smith J, Mosaed S. Shen E, et al. Ocul Immunol Inflamm. 2019;27(8):1339-1341. doi: 10.1080/09273948.2018.1533567. Epub 2018 Oct 18. Ocul Immunol Inflamm. 2019. PMID: 30335586 No abstract available.
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
Kam KW, Chen LJ, Wat N, Young AL. Kam KW, et al. Ocul Immunol Inflamm. 2017 Oct;25(5):663-677. doi: 10.3109/09273948.2016.1158282. Epub 2016 May 18. Ocul Immunol Inflamm. 2017. PMID: 27192186 Review.
PURPOSE: To assess the safety and efficacy of topical olopatadine versus placebo and other topical anti-allergic medications in treating allergic conjunctivitis. ...CONCLUSIONS: Topical olopatadine is a safe and effective treatment modality for allergic conjunctivit …
PURPOSE: To assess the safety and efficacy of topical olopatadine versus placebo and other topical anti-allergic medications in treat …
Immunomodulators for conjunctivitis.
Pacharn P, Vichyanond P. Pacharn P, et al. Curr Opin Allergy Clin Immunol. 2013 Oct;13(5):550-7. doi: 10.1097/ACI.0b013e328364d86a. Curr Opin Allergy Clin Immunol. 2013. PMID: 23974685 Review.
RECENT FINDINGS: Some second generation of antihistamines demonstrated anti-inflammatory properties such as inhibition of histamine release from mast cells as well as interference with the production cytokines and adhesion molecules from cord blood and conjunctival mast cells. Am …
RECENT FINDINGS: Some second generation of antihistamines demonstrated anti-inflammatory properties such as inhibition of histamine release …
416 results